News
NPCE
13.56
-3.21%
-0.45
Weekly Report: what happened at NPCE last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at NPCE last week (0408-0412)?
Weekly Report · 04/15 12:06
Weekly Report: what happened at NPCE last week (0401-0405)?
Weekly Report · 04/08 12:13
‘Time to Hit Buy,’ Says Wells Fargo About These 2 Stocks
Wells Fargo analysts have upgraded their ratings on two names they see as 'Buy' stocks. GoodRx Holdings and NeuroPace are two of the names the analysts at the financial giant have turned bullish on. Both stocks have double-digit upsides and are expected to rise in the coming year. Goodrx is an online pharmacy that streamlines the distribution of prescription medications. NeuroPACE is a company in the medical field of epilepsy.
TipRanks · 04/04 13:20
Weekly Report: what happened at NPCE last week (0325-0329)?
Weekly Report · 04/01 12:09
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
Barchart · 03/27 15:05
Weekly Report: what happened at NPCE last week (0318-0322)?
Weekly Report · 03/25 12:13
Weekly Report: what happened at NPCE last week (0311-0315)?
Weekly Report · 03/18 12:11
NeuroPace Price Target Raised to $20.00/Share From $16.00 by Wells Fargo
Dow Jones · 03/14 13:28
Wells Fargo Upgrades NeuroPace to Overweight, Raises Price Target to $20
Benzinga · 03/14 13:18
The Latest Analyst Ratings For NeuroPace
NeuroPace has an average price target of $16.33. NeuroPace is a medical device company focused on the treatment of epilepsy. The company has a positive revenue growth rate of 40.84% over the past three years. The average 12-month price target for the company is $12.00. 6 analysts have given the company a 'neutral' rating.
Benzinga · 03/12 14:00
NeuroPace Is Maintained at Overweight by JP Morgan
Dow Jones · 03/12 13:17
NeuroPace Price Target Raised to $17.00/Share From $9.00 by JP Morgan
Dow Jones · 03/12 13:17
JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $17
Benzinga · 03/12 13:07
Weekly Report: what happened at NPCE last week (0304-0308)?
Weekly Report · 03/11 12:06
Neuropace, Inc.’s New Economy & Political Environment Risk – A Cause for Worry?
TipRanks · 03/07 06:01
NeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth Drivers
TipRanks · 03/07 04:15
NeuroPace GAAP EPS of -$0.23
Seeking Alpha · 03/06 18:11
NeuroPace Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 03/06 17:38
NeuroPace Price Target Raised to $18.00/Share From $16.00 by Cantor Fitzgerald
Dow Jones · 03/06 17:38
More
Webull provides a variety of real-time NPCE stock news. You can receive the latest news about Neuropace Inc through multiple platforms. This information may help you make smarter investment decisions.
About NPCE
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.